News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search


New agreement provides new medicines, saves millions

Media release

New agreement provides new medicines, saves millions

A new agreement with GlaxoSmithKline (GSK) will see two newly listed medicines, improved access to commonly used asthma inhalers, and millions of dollars of savings.

The agreement with the international pharmaceutical company includes five products, three of which – the asthma inhalers fluticasone (Flixotide), salmeterol (Serevent) and the combination inhaler Seretide – are already funded.

PHARMAC will remove the Special Authority criteria from Seretide, which is currently used by 74,000 New Zealanders with chronic asthma, which will mean anyone whose doctor thinks they need it can have it funded.

PHARMAC will also list the anti-viral influenza treatment zanamavir (Relenza) and the new blood disorder drug eltrombopag (Revolade), while the price will reduce on all three asthma inhalers.

Altogether, the changes will produce savings greater than $20 million over five years.

Director of Operations Sarah Fitt says the agreement is the result of PHARMAC’s negotiations with GSK on its range of products.

“The end result will be an expansion in medicines access for New Zealanders, at a lower cost to the taxpayer,” she says.

“This agreement has several benefits. New medicines are funded, including a new drug for a rare blood disorder. For asthma patients who could benefit from access to Seretide, it makes funded access easier by removing the need to apply for authorisation, lifting an administrative barrier which is in line with the Government’s aim to make healthcare better, sooner and more convenient.”

“And overall, because of the price reduction on asthma inhalers, there will be savings of millions of dollars each year. This is important, because it frees up funding that PHARMAC or District Health Boards can use to purchase other healthcare.”

Sarah Fitt says New Zealand has comparatively high rates of asthma and increasing access to the combination inhaler will be welcomed.

As illustrated in PHARMAC’s 2013 Annual Review, published last week, Seretide is one of the highest-cost medicines by gross spending on the Pharmaceutical Schedule, accounting for $21.4 million of subsidies last year.

Eltrombopag, which can increase blood platelet counts and reduce bleeding risk, will be funded for people with idiopathic thrombocytopenic purpura (ITP), a rare blood disorder which puts people at higher risk of severe bleeding.

Funding for eltrombopag will be targeted to people with more severe forms of ITP, who have already tried other available treatments, including splenectomy (spleen removal).

Changes will take effect from 1 January 2014.


© Scoop Media

Culture Headlines | Health Headlines | Education Headlines


With Hunters & Collectors: The Rolling Stones Announce New Auckland Date

It’s the news New Zealand has been waiting for. The Rolling Stones today confirmed the rescheduled dates and venues for both the Australian and New Zealand legs of their highly anticipated ’14 On Fire’ tour. Now, Frontier Touring is also delighted ... More>>


Flying Things: Conchords, Pretties Help BATS Fly Home

The launch of BATS theatre’s fundraising campaign has taken off – with a bit of help from their friends. And with friends like theirs… An event last night hosted by Te Radar at Wellington’s latest waterfront venue, Shed 6, featured Fly My Pretties and, in a dream-come-true scenario, Flight of the Conchords. More>>


Environment: Zoo’s Own Wētā Workshop Produces Rare Giants For Release

Following unprecedented breeding and rearing success, Auckland Zoo is today releasing 150 of New Zealand’s largest giant wētā, the wētā punga, onto pest-free Motuora Island in the Hauraki Gulf. A further 150 will be released onto Tiritiri Matangi next month. More>>

Girls On Film: Divergent Hits The Big Screen

n January, Catching Fire (the second film in the Hunger Games series) not only became the biggest US box office success of 2013 : it also became the first film starring a female actor (ie. Jennifer Lawrence) to top the annual domestic earnings chart since The Exorcist, 40 years ago. More>>


Wellington.Scoop: No Travel Sanctions For Russian Billionaire’s Superyacht

On the same day that New Zealand announced travel sanctions against selected Russians, a Russian billionaire’s superyacht berthed in Wellington Harbour. More>>


Mental Health: UC Researchers Believe Robots Can Persuade People To Conform

A team of University of Canterbury (UC) researchers and scientists believe robots can persuade people to conform through group pressure... ``Our results showed that robots can induce conformity but to a significantly lesser degree than humans." More>>

NZ On Air: Local Content Holds Steady At 32% Of Television Schedules

Since 1989 NZ On Air has measured local free-to-air television content. The report compares the schedules of the six national free-to-air channels, to observe trends and changes in the local content landscape. More>>

Arts Fest: 2014 New Zealand Festival A Spectacular Celebration

The New Zealand Festival welcomed the world to Wellington over 24 days (21 Feb – 16 Mar) of arts events across the city. “[current figures show] slight increase on the 110,000 tickets issued in 2012. It’s a great result.” More>>

Opera: Happy 70th Birthday Dame Kiri Te Kanawa

Our first lady of song who “feels more like at 15 year old” will celebrate her significant birthday on stage at Covent Garden tomorrow night (Friday morning NZT), performing in the Royal Opera House’s production of La fille du régiment (The Daughter of the Regiment) as La Duchess de Crackentorp. More>>


Get More From Scoop



Search Scoop  
Powered by Vodafone
NZ independent news